D
DR. REDDY’S LABORATORIES LTD ADR
NYSE: RDY (Dr. Reddy's Laboratories Ltd)
Last update: 23 hours ago14.74
0.01 (0.07%)
| Previous Close | 14.73 |
| Volume | 3,713,805 |
| Price / Earnings (Forward) | 31.64 |
| Price / Sales | 3.45 |
| Price / Book | 3.07 |
| 52 Weeks Range | |
| TTM Dividend Yield | 0.68% |
| Profit Margin | 16.99% |
| Operating Margin (TTM) | 20.50% |
| Diluted EPS (TTM) | 0.790 |
| Quarterly Revenue Growth (YOY) | 11.40% |
| Quarterly Earnings Growth (YOY) | 1.90% |
| Total Debt/Equity (MRQ) | 13.75% |
| Current Ratio (MRQ) | 1.89 |
| Operating Cash Flow (TTM) | 52.56 B |
| Levered Free Cash Flow (TTM) | 14.23 B |
| Return on Assets (TTM) | 9.71% |
| Return on Equity (TTM) | 17.71% |
AIStockmoo Score
| Value 30% | 1.7 |
| AI Insight info | NA |
| Relative Valuation info | 0.5 |
| Financial Health info | 3.6 |
| Timing 30% | 1.4 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | -2.5 |
| Sentiment 20% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money 20% | 0.5 |
| Insider Activity info | NA |
| Institutional Flow info | 0.5 |
| Environment | ×0.85 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -4.0% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -2.9 |
| Final Score | 1.10 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Dr. Reddy's Laboratories Ltd | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
| HIMS | - | - | - | 18.72 |
Select this tab to load the latest available analysis.
|
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Large Core |
| % Held by Institutions | 14.04% |
No data within this time range.
Institutions
Institutional ownership: 15.69%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 101 | 25,365,764 |
| Decreased | 132 | 22,778,120 |
| New | 24 | 1,034,173 |
| Sold out | 33 | 1,396,905 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 26 Oct 2026 | Yahoo Finance |
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets. |
| 23 Oct 2026 | Yahoo Finance |
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
Dr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business. Chief Financial Officer M.V. Narasimham said t… |
| 12 Oct 2026 | Yahoo Finance |
Top Stock Reports for Oracle, American Express & Progressive
Oracle, American Express and Progressive face contrasting challenges and growth drivers, from underperformance to rising expenses, premium growth and strategic investments. |
| 25 Aug 2026 | Yahoo Finance |
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks. |
| TTM Dividend Yield | 0.68% |
| 5Y Average Dividend Yield | 1.25% |
| Payout Ratio | 11.71% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 30 Jul 2024 | 09 May 2024 | - | 0.4791739 Cash |
| 01 Aug 2022 | 24 May 2022 | 12 Aug 2022 | 0.3784342 Cash |
| 08 Jul 2021 | 16 Jun 2021 | 11 Aug 2021 | 0.3364846 Cash |
| 10 Jul 2020 | 26 Jun 2020 | 17 Aug 2020 | 0.3333635 Cash |
| 12 Jul 2019 | 12 Jun 2019 | 15 Aug 2019 | 0.282229 Cash |
| 13 Jul 2018 | 12 Jun 2018 | 09 Aug 2018 | 0.291977 Cash |
| 13 Jul 2017 | - | 10 Aug 2017 | 0.293922 Cash |
| 14 Jul 2016 | - | 09 Aug 2016 | 0.279468 Cash |
| 08 Jul 2015 | - | 17 Aug 2015 | 0.29292 Cash |
| 01 Aug 2014 | - | 15 Aug 2014 | 0.271545 Cash |
| 10 Jul 2013 | - | 15 Aug 2013 | 0.225329 Cash |
| 27 Jun 2012 | - | 06 Aug 2012 | 0.227636 Cash |
| 29 Jun 2011 | - | 11 Aug 2011 | 0.234654 Cash |
| 30 Jun 2010 | - | 17 Aug 2010 | 0.22126 Cash |
| 02 Jul 2009 | - | 12 Aug 2009 | 0.110398 Cash |
| 03 Jul 2008 | - | 18 Aug 2008 | 0.071056 Cash |
| 06 Jul 2007 | - | 10 Aug 2007 | 0.074322 Cash |
| 07 Jul 2006 | - | 21 Aug 2006 | 0.10725 Cash |
| 07 Jul 2005 | - | 16 Aug 2005 | 0.11475 Cash |
| 15 Jul 2004 | - | 24 Aug 2004 | 0.10766 Cash |
| 07 Aug 2003 | - | 02 Oct 2003 | 0.10925 Cash |
| 08 Aug 2002 | - | 30 Sep 2002 | 0.04618 Cash |
| 20 Nov 2001 | - | 13 Dec 2001 | 0.1042 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2022 | 0.378 | 1 | 3.66 |
| 2021 | 0.336 | 1 | 2.57 |
| 2020 | 0.333 | 1 | 2.34 |
| 2019 | 0.282 | 1 | 3.48 |
| 2018 | 0.292 | 1 | 3.87 |
| 2017 | 0.294 | 1 | 3.91 |
| 2016 | 0.279 | 1 | 3.09 |
| 2015 | 0.293 | 1 | 3.16 |
| 2014 | 0.272 | 1 | 2.69 |
| 2013 | 0.225 | 1 | 2.75 |
| 2012 | 0.228 | 1 | 3.42 |
| 2011 | 0.235 | 1 | 3.99 |
| 2010 | 0.221 | 1 | 2.99 |
| 2009 | 0.110 | 1 | 2.28 |
| 2008 | 0.071 | 1 | 3.63 |
| 2007 | 0.074 | 1 | 2.05 |
| 2006 | 0.107 | 1 | 2.95 |
| 2005 | 0.115 | 1 | 5.31 |
| 2004 | 0.108 | 1 | 5.43 |
| 2003 | 0.109 | 1 | 3.45 |
| 2002 | 0.046 | 1 | 2.39 |
| 2001 | 0.104 | 1 | 5.50 |
| Show more | |||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |